Tag: Mayan Katz
Three firms act on BioNTech’s USD950m China partner buyout
A&O Shearman, Goodwin, and Conyers are advising BioNTech on its $950M buyout of a Chinese cancer drug partner to rival Merck
A&O Shearman, Goodwin, and Conyers are advising BioNTech on its $950M buyout of a Chinese cancer drug partner to rival Merck
The innovation engine is shifting gear. Whoever recalibrates the timing will lead through the next bend.